Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study

Jean-François Llitjos1,9*, Swann Bredin2, Jean-Baptiste Lascarrou3, Thibaud Soumagne4, Mariana Cojocaru5, Maxime Leclerc6, Arnaud Lepetit6, Albin Gouhier7, Julien Charpentier2, Gaël Piton4, Matthieu Faron8, Annabelle Stoclin9 and Frédéric Pène1,2

Abstract

Background: The aim of this study is to determine whether severe COVID-19 patients harbour a higher risk of ICU-acquired pneumonia.

Methods: This retrospective multicentre cohort study comprised all consecutive patients admitted to seven ICUs for severe COVID-19 pneumonia during the first COVID-19 surge in France. Inclusion criteria were laboratory-confirmed SARS-CoV-2 infection and requirement for invasive mechanical ventilation for 48 h or more. Control groups were two historical cohorts of mechanically ventilated patients admitted to the ICU for bacterial or non-SARS-CoV-2 viral pneumonia. The outcome of interest was the development of ICU-acquired pneumonia. The determinants of ICU-acquired pneumonia were investigated in a multivariate competing risk analysis.

Result: One hundred and seventy-six patients with severe SARS-CoV-2 pneumonia admitted to the ICU between March 1st and 30th June of 2020 were included into the study. Historical control groups comprised 435 patients with bacterial pneumonia and 48 ones with viral pneumonia. ICU-acquired pneumonia occurred in 52% of COVID-19 patients, whereas in 26% and 23% of patients with bacterial or viral pneumonia, respectively (p < 0.001). Times from initiation of mechanical ventilation to ICU-acquired pneumonia were similar across the three groups. In multivariate analysis, the risk of ICU-acquired pneumonia remained independently associated with underlying COVID-19 (SHR = 2.18; 95 CI 1.2–3.98, p = 0.011).

Conclusion: COVID-19 appears an independent risk factor of ICU-acquired pneumonia in mechanically ventilated patients with pneumonia. Whether this is driven by immunomodulatory properties by the SARS-CoV-2 or this is related to particular processes of care remains to be investigated.

Keywords: COVID-19, Ventilator-acquired pneumonia, Immunosuppression, Septic shock

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
clinical features, making it somewhat different from more classical bacterial and viral pneumonia. In the absence of efficient therapy, mechanical ventilation is the cornerstone of the COVID19 management but then exposes patients to ICU-acquired infections.

ICU-acquired pulmonary infections are major complications of invasive mechanical ventilation, responsible for respiratory deterioration, extra-pulmonary organ dysfunctions and prolongation of ventilation and of the length stay in the ICU. Hence, ICU-acquired pneumonia is a frequent complication in critically ill ventilated patients, with incidences ranging from 13.5 to 23%, and accounts for a major cause of morbidity and mortality in septic patients [2]. Prolonged mechanical ventilation represents the leading risk factor of ICU-acquired pneumonia. We also previously reported that septic shock patients with pneumonia exhibited the highest risk of ICU-acquired pneumonia, suggesting that a primary pulmonary insult may drive profound alterations in lung defence towards a secondary infectious insult [3]. As a matter of fact, sepsis-induced immunosuppression as assessed by quantitative and functional defects in circulating immune cells has been associated with increased susceptibility to secondary ICU-acquired infections (ICU-AI) [4]. Whether COVID-19 patients harbour different susceptibility towards secondary infections have not been investigated.

To address these questions, we investigated the incidence and the determinants of ICU-acquired pneumonia in mechanically ventilated COVID-19 patients, as compared to control patients with severe bacterial or viral pneumonia.

Methods
Study design and participants
We performed a retrospective study in seven ICUs within six French hospitals. The study gathered consecutive adult patients (aged ≥ 18 years old) admitted to the ICU with a PCR-confirmed SARS-CoV-2 pneumonia requiring mechanical ventilation. Only patients who received endotracheal intubation during the first two days following ICU admission and required mechanical ventilation for at least 48 h were included. COVID-19 patients were compared to mechanically ventilated patients with community-acquired bacterial or viral pneumonia, extracted from a retrospective 2008–2017 database of the medical ICU of Cochin hospital [3]. The Research Ethics Committee of the Institut Gustave Roussy approved the study and waived the need for patient’s consent. The study was registered at the French National Commission on Informatics and Liberty and at the French National Institute for Health Data. The ethics committee of the French Intensive Care Society had previously approved the constitution of the historical database (ref. CE SRLF, #16–30).

Data collection
Demographic, clinical, laboratory, treatment and organ support at baseline, and outcome data were collected from electronic medical records using a standardized data collection form. Given the protracted mechanical ventilation that were observed in COVID-19 patients at the beginning of the outbreak [5], the observation period was extended to day 45.

Definitions
Laboratory confirmation of COVID-19 was based upon SARS-CoV-2 detection by real-time RT-PCR from nasal swabs or lower respiratory tract secretions. Obesity was defined as a body mass index superior to 30 kg/ m². Patients were considered immunocompromised if one or more of the following conditions were observed: patients with solid tumours with chemotherapy in the last 3 months or a progressive metastatic disease, hematologic malignancies, solid organ transplantation, HIV infection with or without AIDS, treatment with corticosteroids (> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for > 7 day), or treatment with other immunosuppressive drugs. Severity at admission was assessed by the Simplified Acute Physiology Score 2 and the Sequential Organ Failure Assessment (SOFA) scores. Acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin definition [6].

ICU-acquired pneumonia was defined as new onset of probable or definite infection not present at the time of ICU admission and that developed after the first 48 h from ICU admission. Only the first episode of ICU-acquired pneumonia was considered for the present analysis. ICU-acquired pneumonia diagnosis was based on a Clinical Pulmonary Infectious Score > 6 [7]. Patients with clinically suspected ICU-acquired pneumonia were subjected to a tracheobronchial aspirate or broncho-alveolar lavage with direct Gram staining and semi-quantitative culture [7]. Invasive fungal infections were diagnosed according to current guidelines [8]. An independent physician (JFL) retrospectively assessed the diagnostic accuracy of all episodes of ICU-acquired pneumonia.

Patient management
Management of sepsis and septic shock was in accordance with the guidelines of the Surviving Sepsis Campaign [9]. Antimicrobial treatments were administered intravenously depending on the clinical suspicion of infection and known colonization with antibiotic-resistant bacteria and deescalated to narrower spectrum after identification of the responsible pathogen. Management
of ARDS in the COVID-19 cohort followed the French Intensive Care Society guidelines [10]. Strategies to prevent ICU-acquired pneumonia were implemented according to guidelines and included the use of weaning protocols, semi-recumbent position, enteral route feeding and physiotherapy [7]. End-of-life decisions to withhold or withdraw life support were taken independently at each centre and palliative care was then appropriately delivered in the ICU.

Statistical analysis
Continuous variables were expressed as median (inter-quartile range) and categorical variables as numbers (percentages) and were compared by the Kruskal–Wallis' test, the Pearson's Chi-square test or the Fisher's exact test as appropriate. The independent predictors of ICU death were investigated through a multivariate Fine–Gray model analysis to fit cumulative incidence curves. The model included variables that reached p value less than 0.20 in univariate analysis.

Determinants of ICU-acquired pneumonia were analysed through a competing risk framework, with death in ICU and extubation for more than 48 h as competing events. Independent determinants of ICU-acquired pneumonia were investigated in a multivariate analysis using a Fine–Gray model to fit cumulative incidence curves. We also investigated the determinants of ICU-acquired pneumonia using a cause-specific Cox model. The model included variables that reached p values of less than 0.20 in univariate analysis and proportional hazard assumption was checked using graphical diagnostics based on the scaled Schoenfeld residuals. All analyses were carried out using R 3.3.3 (R foundation for Statistical Computing Vienna, Austria).

Results
COVID-19 and non-COVID-19 cohorts
Between March 1st and 30th June of 2020, 176 patients were admitted in ICU for severe SARS-CoV-2 pneumonia requiring invasive mechanical ventilation for more than 48 h. Their main characteristics are summarized in Table 1. Arterial hypertension and obesity were the prominent comorbid conditions. Time from symptoms onset to ICU admission was 7.5 (4.25–10) days. About one-third of COVID-19 patients (n = 66, 37%) received specific antiviral treatments, including hydroxychloroquine and azithromycin combination in 39 patients, lopinavir in 18 patients and remdesivir in 8 patients. Twelve COVID-19 patients (6%) were treated with steroids (dexamethasone) and one patient received tocilizumab. Bacterial co-infection was documented in 21 (12%) patients. Nearly all patients fulfilled the criteria for ARDS (n = 170, 96%) and most of them underwent prone positioning (n = 130, 74%) with a median number of 3 (1–7) sessions. Rescue veno-venous extracorporeal membrane oxygenation (ECMO) was used in 10 patients. The overall ICU mortality rate was 31% (n = 55) and the median duration of mechanical ventilation was 17 days (25th–75th IQR: 10–28). Half of patients (49%) with bacterial pneumonia received stress-dose hydrocortisone for acute circulatory failure.

Control groups were patients with severe bacterial (n = 435) or viral (n = 48) pneumonia. Their characteristics are displayed in Table 1, and compared with those of COVID-19 patients. All cases of viral pneumonia were related to influenza virus, except two episodes related to metapneumovirus and cytomegalovirus. Bacterial co-infection was documented in 11 (24%) patients with viral pneumonia. The overall ICU mortality was 33% in patients with bacterial pneumonia and 25% in viral pneumonia.

COVID-19 and non-COVID-19 patients markedly differ in a number of underlying characteristics and clinical presentation of acute condition (Table 1). Although COVID-19 patients exhibited lower admission severity scores, they more often fulfilled the diagnostic criteria for ARDS. COVID-19 finally exhibited increased duration under mechanical ventilation (median 17 days vs. 8 days in bacterial pneumonia and 7 days in viral pneumonia, p < 0.001) and eventually increased length of stay in the ICU (median 20 days vs. 10 days in bacterial pneumonia and 9 days in viral pneumonia, p < 0.001). In-ICU mortality rates of COVID-19 and bacterial pneumonia were similar (31% and 33%, respectively), both slightly higher than that of viral pneumonia (25%). However, the mortality rates did not differ across even after adjustment with other confounders (Additional file 1: Table S1).

ICU-acquired infections in COVID-19 and non-COVID-19 patients
The frequency of ICU-acquired pneumonia was 52% in COVID-19 patients, with a median time from intubation to diagnosis of 9 (6–14) days (Fig. 1). ICU-acquired pneumonia was responsible for deterioration to septic shock in half of cases. Patients with bacterial pneumonia and viral pneumonia exhibited lower ICU-acquired pneumonia frequencies of 26% and 23%, respectively (Table 2). Times from intubation to ICU-acquired pneumonia were 9 (6–12) days in bacterial pneumonia and 7 (6.5–14) days in viral pneumonia, thereby similar to that of COVID-19 patients. The distribution of causing pathogens is precised in Table 2. In multivariate analysis taking into account mechanical ventilation as a time-dependent variable, the independent determinants of ICU-acquired pneumonia were COVID-19 pneumonia (SHR = 2.18; 95% CI 1.2–3.98, p = 0.011), male gender (SHR = 1.55;...
Table 1  Characteristics and outcome of patients with COVID-19, bacterial pneumonia or viral pneumonia

| Variables                                      | COVID-19 (n = 176) | Bacterial pneumonia (n = 435) | Viral pneumonia (n = 48) | p       |
|------------------------------------------------|--------------------|-------------------------------|--------------------------|---------|
| Age, years                                     | 63 (55–73)         | 66 (56–79)                    | 72 (42–75)               | 0.002   |
| Male gender                                    | 134 (76)           | 296 (68)                      | 25 (52)                  | <0.001  |
| Body mass index, kg/m²                         | 28.2 (26–32.3)     | 23.4 (20.7–26.7)              | 23 (19.2–28.9)           | <0.001  |
| Comorbid conditions                            | Immunosuppression  | 26 (15)                       | 145 (33)                 | <0.001  |
|                                                | Cirrhosis          | 2 (1)                         | 41 (9)                   | <0.001  |
|                                                | Diabetes mellitus  | 45 (26)                       | 89 (21)                  | 0.181   |
|                                                | COPD               | 17 (10)                       | 103 (24)                 | <0.001  |
|                                                | Chronic renal failure | 13 (7)                     | 49 (11)                  | 0.22    |
|                                                | Cancer (ongoing or < 5 years) | 16 (9)                  | 120 (28)                 | <0.001  |
| Severity on ICU admission                      | SAPS2, points      | 43 (30–56)                    | 73 (55–88)               | <0.001  |
|                                                | SOFA, points       | 6 (4–9)                       | 9 (6–2)                  | <0.001  |
| Biological findings                            | WBC count, per mm$^3$ | 8.4 (6.9–12.4)              | 12 (6.2–17.6)            | <0.001  |
|                                                | Lactate, mmol/L    | 1.5 (1.2–1.9)                 | 1.7 (1–3.8)              | 0.02    |
| Characteristics of pneumonia                  | Septic shock (Sepsis-3) | 28 (16)                    | 191 (44)                 | <0.001  |
|                                                | ARDS               | 170 (96)                      | 62 (14)                  | <0.001  |
|                                                | Microbiological documentation | 21 (12)              | 286 (66)                 | <0.001  |
|                                                | Gram-negative bacteria | 11 (7)                   | 148 (34)                 | <0.001  |
|                                                | Gram-positive cocci | 10 (6)                       | 126 (30)                 | 6 (13)  |
|                                                | SARS-CoV-2         | 176 (100)                     | 0                        |         |
|                                                | Influenza virus    | 0                            | 0                        | 46 (96) |
|                                                | Miscellaneous      | 0                            | 12 (3)*                  | 2 (4)** |

ICU management within the first 48 h

| Antimicrobial agents                           | 161 (92)           | 435 (100)                     | 45 (94)                  | <0.001  |
| Vasopressors                                   | 371 (85)           | 147 (83)                     | 37 (71)                  | 0.32    |
| Prone positioning                              | 130 (74)           | 41 (9)                       | 9 (19)                   | <0.001  |
| Number of sessions                             | 3 (2–5)            | 2 (1.5–2.5)                  | 1 (1–2)                  | <0.001  |
| Anaesthesia ventilator                         | 12 (7)             | 0 (0)                        | 0 (0)                    | <0.001  |
| Extracorporeal membrane oxygenisation          | 10 (6)             | 14 (3)                       | 5 (10)                   | 0.04    |
| Renal replacement therapy                      | 51 (29)            | 44 (10)                      | 9 (19)                   | <0.001  |
| Blood transfusions                             | 67 (38)            | 223 (51)                     | 18 (37)                  | 0.01    |
| Corticosteroids                                | 12 (6)             | 213 (49)                     | 0 (0)                    | <0.001  |

Outcomes

| Total duration of mechanical ventilation, days | 17 (10–28)       | 8 (5–16)                     | 7 (4–13)                 | <0.001  |
| ICU length of stay, days                      | 20 (12–30)       | 10 (6–19)                    | 9 (6–16)                 | <0.001  |
| ICU mortality                                 | 55 (31)          | 143 (33)                     | 12 (25)                  | <0.001  |

95% CI 1.14–2.12, p = 0.005), ARDS (SHR = 1.84; 95% CI 1.25–2.72, p = 0.002) and duration of mechanical ventilation (SHR = 1.027, 95% CI 1.01–1.04, p ≤ 0.001) (Table 3). Of note, because control cohorts were obtained from one centre, this variable was considered in our statistical analysis and was not associated with ICU-acquired pneumonia.
Discussion

COVID-19 pandemic has shed light on the risk of shortage in ICU beds related to the surge of ICU admissions, but also to prolonged bed occupancy by patients with sustained respiratory failure. Protracted mechanical ventilation in SARS-CoV-2 pneumonia can be primarily ascribed to the severity of the lung injury, but also to the development of secondary complications. In this study, we addressed the specific risk of ICU-acquired pneumonia in the course of severe. When compared to recent cohorts of patients with non-COVID-19 pneumonia, patients with severe SARS-CoV-2 pulmonary infection exhibited a prominent risk of ICU-acquired pneumonia.

Other studies have already reported various frequency rates of ICU-acquired pneumonia in mechanically ventilated COVID-19 patients, with estimated incidence ranging from 16 to 31% in two early reports from China [11, 12]. Since then, several studies confirmed this impression [13–16]. Importantly, an accurate estimation for the cumulative risk of ICU-acquired pneumonia in ventilated patient requires handling two main competing events that are extubation and death to avoid misinterpretation of risks. The high rate of ICU-acquired pneumonia in COVID-19 patients may result from a particular susceptibility to pulmonary superinfections. The question is whether COVID-19 stands as risk factor of ICU-acquired infections on its own, or if this association is rather related to confounding factors such as exposure to invasive devices or significant changes in care practice. Such a retrospective study can hardly provide a definite answer between causality and association, despite investigating the potential confounders and entering them into multivariate models. Since ICU-acquired pneumonia is strongly associated with the duration under invasive mechanical ventilation, we treated mechanical ventilation as a time-dependent covariate in multivariate analysis [17]. Nonetheless, it is noteworthy that times from intubation to the first episode of ICU-acquired pneumonia were similar across the three groups. Of note, nearly all patients from the three groups had received antibiotics in the early days in the ICU. The increased risk

![Fig. 1 Cumulative incidence of ventilator-associated pneumonia among patients](image)

| ICU-acquired pneumonia | COVID-19 (n=92) | Bacterial pneumonia (n=113) | Viral pneumonia (n=11) | p |
|------------------------|---------------|-----------------------------|-----------------------|---|
| Frequency              | 92 (52)       | 113 (26)                    | 11 (23)               | <0.001 |
| Time from intubation to first ICU-AP, days | 9 (6–14) | 9 (6–12) | 7 (6.5–14) | 0.70 |
| Deterioration to septic shock | 45 (49) | 72 (64) | 5 (45) | 0.01 |
| Microbiological documentation | | | | |
| Enterobacteriaceae | 50 | 27 | 3 | <0.001 |
| Non-fermenting GNB | 20 | 114 | 7 | |
| Gram-positive cocci | 28 | 3 | 1 | |
| Polymicrobial | 24 (16) | 19 (17) | 2 (4) | |
| Fungi | 1 | 2 | 0 | |
| Subsequent episodes of ICU-AP | | | | |
| Second | 37 (21) | 53 (12) | 3 (6) | |
| Third | 15 (8) | 37 (8) | 3 (6) | |
| Fourth | 2 (1) | 12 (3) | 0 | |

ICU, intensive care unit; ICU-AP, intensive care unit-acquired pneumonia. Variables are expressed as median (interquartile range) or number (percentage) as appropriate
of ICU-acquired pneumonia may also be related to increased workload that may have prevented strict and thorough implementation of preventive bundles.

COVID-19 has emerged as a particular infection with a characteristic two-step course in a significant proportion of patients. Whereas the primary symptoms are associated with viral shedding, secondary respiratory deterioration is associated with potent systemic acute inflammatory response. The pathophysiology of COVID-19 lung involvement encompasses endothelial and epithelial alterations as well as pulmonary embolism and microvascular thrombosis. Besides, secondary infectious insults sustain acute lung injury and likely contribute to prolonged mechanical ventilation. The particular susceptibility of post-COVID critically ill patients to ICU-acquired pneumonia suggests defective anti-infective immune responses against bacterial superinfections reminiscent of those observed in post-septic patients [18]. Sepsis-induced immunosuppressive response is related to various quantitative and functional alterations in most immune cells [4]. Whether such immune dysfunctions may also account for increased susceptibility to secondary infections in COVID-19 patients remains to be investigated.

Interventions studies for severe COVID-19 have so far attempted dampening the primary pro-inflammatory cytokine response by anti-inflammatory compounds, most especially to prevent the respiratory deterioration of patients with mild pneumonia. There is no signal so far that such early immunomodulatory therapeutics of COVID-19 may increase the risk of secondary infections. However, the particular susceptibility of COVID-19 patients to secondary bacterial infections raises the question of immunostimulant strategies later on in the ICU. For instance, drugs known to restore monocyte functions and HLA-DR and CD14 expressions such as interferon gamma (IFNγ) or GM-CSF, or drugs to restore lymphocyte activation such as IL-7 or thymosin-α may represent attractive therapeutic options in this setting [19].

This study has several limitations. Although improving the external validity, the multicentre design also harbours the risk of inconsistent care and diagnostic procedures. The diagnosis of ICU-acquired pneumonia was let at the discretion of the physician in charge, with the help of a validated score, and was reviewed by an independent investigator to ensure appropriate and consistent diagnosis. Data from severe COVID-19 patients were obtained from seven different ICUs, whereas controls with bacterial and viral pneumonia were obtained from one single centre. However, frequencies of secondary pneumonia in COVID-19 patients were consistent across centres, and the centre effect was taken into account in

Table 3 Determinants associated with ICU-acquired pneumonia using sub-distribution hazard ratio in univariate and multivariate analysis

| Variables group | Univariate | Multivariate |
|-----------------|------------|--------------|
|                 | SHR 95% CI | p            | SHR 95% CI | p            |
| Group           |            |              |            |              |
| Bacterial pneumonia | Ref Ref Ref Ref Ref Ref |          |            |            |
| COVID‑19        | 1.52       | 1.17–1.98    | 0.001      | 2.18        | 1.21–3.98   | 0.011      |
| Viral pneumonia | 0.8        | 0.46–1.42    | 0.46       | 0.76        | 0.43–1.36   | 0.35       |
| Male gender     | 1.67       | 1.23–2.27    | 0.001      | 1.55        | 1.14–2.12   | 0.005      |
| Obesity         | 1.25       | 0.96–1.63    | 0.094      |             |             |            |
| Immunosuppression | 0.68    | 0.5–0.93    | 0.02       |             |             |            |
| Admission SAPS2, per point | 0.99 | 0.99–1 | 0.06 |               |            |            |
| Admission SOFA, per point   | 0.97 | 0.95–1 | 0.15 |               |            |            |
| COPD            | 0.65       | 0.45–0.97    | 0.032      |             |             |            |
| Cancer          | 0.73       | 0.52–1.04    | 0.081      |             |             |            |
| Prone positioning | 1.03 | 1–1.07 | 0.075 |               |            |            |
| Vasopressors    | 1.42       | 0.97–2.08    | 0.073      |             |             |            |
| Blood transfusion | 1.21 | 0.93–1.57 | 0.15     |             |             |            |
| Conventional respiratory device | 0.39 | 0.21–0.73 | 0.03 |               |            |            |
| Antimicrobial treatment | 0.46 | 0.24–0.9 | 0.023 |               |            |            |
| ARDS            | 1.61       | 1.39–2.37    | <0.001     | 1.84        | 1.25–2.72   | 0.002      |
| Duration of MV prior to VAP, days | 1.02 | 1.02–1.04 | <0.001 | 1.027 | 1.01–1.04 | <0.001 |

SAPS2, Simplified Acute Physiology Score 2; COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome; MV, mechanical ventilation. All covariates are analysed at baseline except for mechanical ventilation that was evaluated as time-dependent covariate.
the multivariate models. Most importantly, such a retrospective study is limited to establish a definite causality inference, although we aimed at taking into account major determinants of ICU-acquired pneumonia in the multivariate model.

Conclusion
We identified SARS-CoV-2 infection as an independent risk factor of ICU-acquired pneumonia among mechanically ventilated patients with common bacterial and viral causes of pneumonia. This justifies a thorough reinforcement of preventive measures in these high-risk patients. In the light of immunomodulatory approaches to treat COVID-19, our results raise the question of immunostimulant therapies to fight bacterial superinfections in critically ill COVID-19 patients.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13613-021-00812-w.

Acknowledgements
None.

Authors’ contributions
JFL designed the study, performed statistical analysis and wrote manuscript. SB, JBL, TS, MC, ML, AL, AG, JC, GP and AS collected data and wrote manuscript. MF performed and supervised statistical analysis. FP designed the study and wrote manuscript. All authors read and approved the final manuscript.

Funding
The funder of the study (French Agence Nationale de la Recherche) had no role in study design, data collection, analysis or interpretation and concerned only the cytometric analysis of the study.

Availability of data and materials
Data and material are available under request.

Ethics approval and consent to participate
The Research Ethics Commission of the Institut Gustave Roussy approved the study. The study was registered at the French National Commission on Informatics and Liberty and at the French National Institute for Health Data. The ethics committee of the French Intensive Care Society had previously approved the constitution of the historical database and waived the need for patients’ consents (ref. CE SRLF, #16–30).

Consent for publication
Not applicable.

Competing interests
F Pène: Alexion Pharma (grant paid to his institution) and Gilead (consultancy and lecture fees).

Author details
1 3rd Department, Team Pulmonary and Systemic Immune Responses During Acute and Chronic Bacterial Infections, Institut Cochin, INSERM U1016, CNRS UMR8104, Université de Paris, Paris, France. 2 Medical Intensive Care Unit, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, APHP, Centre, Paris, France. 3 Intensive Care Unit, Hôpital Hôtel-Dieu, Nantes, France. 4 Intensive Care Unit, Hôpital Jean Minjoz Hospital, Besançon, France. 5 Surgical Intensive Care Unit, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, APHP, Centre, Paris, France. 6 Intensive Care Unit, Centre Hospitalier Mémorial France Etats-Unis, Saint-Lô, France. 7 Intensive Care Unit, Centre Hospitalier Intercommunal Alençon Mamers, Alençon, France. 8 Department of Biostatistics and Epidemiology, INSERM UNIT 1018 CESP Oncostat Team, Gustave Roussy Cancer Campus, Villejuif, France. 9 Intensive care unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Received: 20 September 2020 Accepted: 18 January 2021
Published online: 29 January 2021

References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
2. Melsin WG, Rovers MM, Gouwendon RHH, Bergmans DCJJ, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665–71.
3. Llitjos J-F, Gassama A, Charpentier J, Lambert J, de Roquetaillade C, Carion A, et al. Pulmonary infections prime the development of subsequent ICU-acquired pneumonia in septic shock. Ann Intensive Care. 2019;9(1):39.
4. Holchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–8.
5. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle Region—case series. N Engl J Med. 2020;382(11):2012–22.
6. Acute Respiratory Distress Syndrome: the Berlin Definition. JAMA. 2012;307(23):2527–33.
7. De Pauw B, Walsh TJ, Donnelly JP, Stevens JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;46(12):1813–21.
8. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock. 2016. Crit Care Med. 2017;45(3):486–522.
9. Papazian L, Aubron C, Brochard L, Chiche J-D, Combes A, Dreyfus D, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):66.
16. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2020.

17. van Vught LA, Klein Klouwenberg PMC, Spitoni C, Scicluna BP, Wiewel MA, Horn J, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315(14):1469–79.

18. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605.

19. Payen D, Faivre V, Miëtton J, Leentjens J, Brumpt C, Tissières P, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019. https://doi.org/10.1186/s12879-019-4526-x.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.